Genprex Q2 2025 Earnings Report

Genprex EPS Results

• Actual EPS: -$187.00
• Consensus EPS: -$781.00
• Beat/Miss: Beat by +$594.00
• One Year Ago EPS: N/A

Genprex Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Genprex Announcement Details

• Quarter: Q2 2025
• Date: 8/14/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Genprex (NASDAQ:GNPX), Inc. is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes. This preclinical program seeks to deliver genes that support insulin production and glucose regulation, laying the groundwork for future clinical development in metabolic diseases. By leveraging its gene delivery platform, the company aims to expand its pipeline into other oncology and metabolic indications over time.

Headquartered in Austin, Texas, Genprex operates under a management team with deep experience in gene therapy research and biopharmaceutical development. The company collaborates with leading academic and clinical research centers to conduct its studies, ensuring rigorous trial design and patient enrollment. Through these partnerships, Genprex seeks to translate cutting-edge genetic science into transformative therapies for patients with high-unmet medical needs.